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INTRODUCTION
Substantial improvements in maternal and child health have been achieved since 2000, with reductions in child deaths from infectious diseases [1] . However, reducing neonatal deaths, and stillbirths, remains challenging [2] . Of the estimated 6.3 million deaths in children under 5 years in 2013 [3] , 2.8 million (44%) of these deaths were in the neonatal period (0-27 days) and 0.42 [95% confidence interval (CI) 0.27-0.69] million of neonatal deaths were because of sepsis [1] .
The global burden of morbidity because of neonatal infection was estimated at 3% of all Disability Adjusted Life Years [4] , but this estimate excludes long-term morbidity, owing to a lack of data on impairment outcomes [5] . With an estimated 6.9 (95% CI 5.5-8.3) million cases of possible severe bacterial infection (pSBI) in neonates in South Asia, sub-Saharan Africa and Latin America in 2012, improving our understanding of the burden of morbidity is essential [6 & ]. Reducing the burden of neonatal mortality and morbidity depends on the scale-up of essential interventions, which if universally achieved could reduce neonatal mortality by over two-thirds [7 & ]. These interventions include prevention and management of preterm birth, basic and comprehensive obstetric care, immediate newborn care (including resuscitation and antisepsis measures), supportive care, especially for preterm neonates (including kangaroo mother care) and effective management of neonatal infections [7 & ,8,9] . Improving management of neonatal infections depends on effective guidelines, and overcoming barriers to implement them [7 & ]. Here the challenges of the rational development of guidelines in developing countries for the management of neonatal sepsis are identified and discussed.
DIAGNOSIS
Neonatal diseases are difficult to diagnose clinically because signs and symptoms are much more nonspecific for infectious syndromes (sepsis, pneumonia or meningitis) than in older children. The same clinical signs can be present, for example, in neonates born preterm (<37 weeks' gestation), with intrapartum complications, or viral illnesses, with or without concurrent bacterial infection [6 & ]. In developing countries, diagnoses are usually made by healthcare workers without specialist training. To support diagnoses of pSBI and guide treatment, clinical algorithms have been developed, described in the Integrated Management of Childhood Illness [10] . These algorithms have been informed by research, including the first WHO Young Infants Clinical Signs Study (YICSS) [11] , and the second YICSS, which included a focus on neonates in the first week of life [12] . In the second YICSS study, seven clinical signs [fast breathing (respiratory rate >60 breaths per minute), severe chest in-drawing, hyperthermia more than 37.58C, hypothermia less than 35.58C, no movement or movement only on stimulation, convulsions, poor feeding] had 85% sensitivity and 75% specificity for severe bacterial infection in the first week of life, with an experienced paediatrician's diagnosis as the gold standard [12] . Subsequent meta-analysis of six studies validating the use of this algorithm against physician diagnosis (with supporting laboratory data) found a similarly high sensitivity (87%), but specificity was lower (62%) [13] . Fast breathing has been identified as having low specificity as a single sign [14 && ], and hypothermia may be influenced by the environment, for example in Nepal just under half of all neonates were reported to have hypothermia (32.0-36.08C) [15] .
There are particular settings in which low specificity is problematic. If the algorithm is used in the community to facilitate identification and treatment of neonates [16] , and the prevalence of neonatal infection is much lower than in those seeking healthcare, the positive predictive value using this algorithm will be lower (<50%) [6 & ]. In clinical trials, low specificity may introduce misclassification of disease, as described for treatment trials of pneumonia [17 & ]. In current clinical trials for simplified antibiotic treatment, the YICSS algorithm has been amended to increase specificity; fast breathing is not included as a single sign for case definition, the temperature threshold was increased from 37.58C or higher to 38.08C or higher, and poor feeding had to be confirmed by observation. In addition, neonates with convulsions were excluded from the study of simplified treatments, as they were considered to have critical illness. It is important that standardized case definitions for pSBIs in neonates are used, but with the flexibility to evolve, as more sensitive and specific clinical signs and diagnostic strategies are identified.
In developed countries, clinical diagnosis of severe bacterial infection in neonates is supported by experienced paediatricians and systematic laboratory investigation, including conventional microbiological (blood, cerebrospinal fluid and urine), haematological and biochemical tests. However, even with the expertise and investigations available in developed countries, diagnosis remains a challenge [18] . Microbiological identification of a pathogen isolated from blood cultures can confirm a clinical diagnosis of neonatal sepsis, and has high specificity, but sensitivity is lower. Although blood culture sensitivity has been improved with automated blood culture systems (such as BACTEC, BactTALERT), it is still likely less than 80%, particularly with small (<1 ml) blood volumes, common from neonatal samples, and if the colony-forming unit is low (<4 CFU/ml) [19] .
Molecular microbiology, using nucleic acid testing (NAT), may improve diagnostics. There are rapid advances in the use of NAT tests to diagnose and determine the cause of diarrhoea and meningitis, both in terms of sensitivity and implementation in developing countries [20] [21] [22] . However, high sensitivity can present problems in interpretation, and careful case-control studies are required to establish attributable fractions of disease using these methods [23] . Experience of molecular methods to improve diagnosis in developing countries is more limited for neonatal sepsis than for pneumonia [24] , diarrhoea [20] or meningitis [25] , but NAT using the Taqman Array Card is being used in a large ongoing multisite study of the Aetiology of Neonatal Sepsis in South Asia (ANISA) [26 In both developed and developing settings, there is a risk of overtreatment for neonatal sepsis, as sensitivity is prioritized over specificity, owing to high case fatality risk if neonatal sepsis is untreated. However, unnecessary treatment is not without risk in terms of possible side-effects of treatment, especially with over-dosing, reported in one-fifth of neonatal cases in a study in district hospitals in the Kilimanjaro region of Tanzania [28] . Unnecessary treatment and admission to hospital also increase the risk of invasive fungal infections, hospitalacquired bacterial infections and reduced antibiotic susceptibility [29] . A rapid diagnostic test, if it was available, would transform care [30] , directing treatment to those who needed it, and preventing unnecessary antibiotic use.
CAUSE
Differences in the cause of neonatal sepsis in developed and developing countries may reflect true differences in disease epidemiology, as well as differences in the levels of care available to support survival of preterm and/or low-birth-weight neonates. They may also be because of study methodologies, including the quality of microbiological investigations, and study design, particularly whether community or health facility based. There are very limited community-based studies [31, 32] of neonatal infection in developing countries.
In early-onset neonatal sepsis (0-6 days of life), the most commonly reported pathogens in developing countries include Gram negatives (Escherichia coli, Klebsiella pneumoniae) and Gram positives (Staphylococcus aureus) [33] [34] [35] . These early-onset infections may include hospital-acquired infections, if associated with hospital delivery in developing countries, where inadequate hygiene and antisepsis measures contribute to early-onset infections [36] . For late-onset neonatal sepsis, the most common pathogens reported in developing countries are mainly Gram positive, including S. aureus, S. pneumoniae, S. pyogenes, S. agalactiae and some Gramnegative nontyphoidal Salmonellae spp. [33] [34] [35] .
Streptococcus agalactiae [Group B Streptococcus (GBS)], although the leading pathogen in earlyonset infections in developed countries [37, 38] , is less consistently reported in developing countries, particularly studies of community-acquired bacteraemia. However, in a recent systematic review, although in Southeast Asia the estimated burden of GBS disease in infants was low [0.02/1000 live births (95% CI 0.00-0.07)], Africa was estimated to have the highest incidence of GBS in infants worldwide [1.21/1000 live births (95% CI 0.50-1.91)], although based on only four studies [39] [40] [41] [42] , meeting selection criteria [43] . In contrast, the WHO study in The Gambia, Ethiopia, The Philippines and Papua New Guinea in the 1990s investigated 2398 infants attending as outpatients [44] , and isolated GBS in blood cultures from only two infants. Most recently, the WHO study in Bangladesh, Bolivia, Ghana, India, Pakistan and South Africa investigated 782 infants, and there were no isolates of GBS [45] . These differences may reflect true differences, particularly in disease-causing serotypes [46] ; however, this study excluded the most severely ill neonates, and it is possible that with delays in accessing care, neonates with GBS died prior to arrival, especially in early-onset GBS sepsis [43] , for which the case fatality risk is three times higher in developing countries (12.6%, 95% CI 10.8-14.9) than in developed countries (4.6%, 2.1-9.1) [43] .
The role of coagulase-negative Staphylococci in neonatal sepsis in developing countries is not defined; in developed countries, they are the leading cause of late-onset sepsis [37] , but occur mainly in very preterm neonates in intensive care, with ventilator support and indwelling devices [47] . In developing countries, the burden of preterm birth is high [48, 49] , but mortality is also very high [1, 49] . Supportive care is much more limited, so indwelling devices and invasive ventilation are much less frequently used [50] , and, if in use, are restricted to referral centres in urban settings. In this context, it is unclear the extent to which coagulase-negative Staphylococci acts as a neonatal pathogen; it is sometimes reported [51] [52] [53] [54] [55] [56] , but at other times excluded as a contaminant [39, 45, [57] [58] [59] [60] .
Issues of contamination are important for other common skin colonizers, such as S. aureus. Although S. aureus does cause disease, the dominance of S. aureus reported in some studies in developing countries [41, 45, 61] may in part be because of contamination from skin colonization and inadequate site sterilization when blood cultures are taken [45] .
TREATMENT
Empirical treatment for neonatal sepsis, recommended in current WHO guidelines, is intravenous ampicillin (or penicillin) plus gentamicin for 7 days [62] . Cloxacillin is an alternative if Staphylococcal infection is suspected. Third-generation cephalosporins, increasing in availability, particularly in Asia [13] , are used as the second line for those not responding after 48-72 h of treatment. Despite the inconsistent literature on GBS infections, neonatal treatment (but not intrapartum antibiotic prophylaxis) is also recommended for 48 h (and then review) for neonates born to mothers with PROM (>18 h), maternal fever 38 o C or higher before delivery or during labour and foul-smelling amniotic fluid [62] .
Treatment guidelines include admission to hospital, but care seeking can be low (varying from 10 to 100% in low and middle-income countries) [63] . Clinical trials based in Africa and South Asia are assessing whether current antibiotic regimens can be simplified, to facilitate access to care [14 && ]. The Simplified Antibiotic Therapy Trial (SATT) Bangladesh, SATT Pakistan and African Neonatal Sepsis Trial, with harmonized protocols [64 & ], aim to evaluate standard 7-day treatment (daily injection procaine penicillin and gentamicin) compared with combinations of injectable antibiotics and oral amoxicillin [14 && ]. The success of treatment, however, depends on pathogens being susceptible to treatment choices. Data are limited, but there is increasing evidence for reduced susceptibility in pathogens causing both hospital-acquired infections [36] and communityacquired infections, particularly Klebsiella spp. and S. aureus [33, 65, 66] . In an assessment of WHO treatment guidelines, for hospital-acquired infection, around one-third of neonatal sepsis isolates were estimated to be susceptible to first-line antibiotics [36] , and half of Gram negatives (Klebsiella spp. and E. coli) to second-line treatment [36] . K. pneumoniae is a particularly important neonatal pathogen, both in terms of its prevalence, and ability to persist in environments [67,68 & ] and cause persisting outbreaks of hospital-acquired infections, which can be highly resistant to treatment [68 & ]. Community-based studies with antibiotic susceptibility data are limited, but in a systematic review including 11 studies, 57% of bacterial isolates were estimated to be susceptible to benzylpenicillin/ ampicillin and gentamicin, and 56% susceptible to third-generation cephalosporins [33] . Recent work supports these findings; 40 Gram-negative neonatal pathogens were isolated as part of the WHO study across six countries and 38/39 (97%) showed resistance to ampicillin, 17/39 (44%) to gentamicin and 19/31 (61%) to third-generation cephalosporins [45] . Alternative therapeutic options, such as fluoroquinolones and carbapenems, are limited and expensive for developing countries.
SUPPORTIVE CARE
Respiratory support, intravenous fluids, phototherapy, temperature and glucose regulation as well as prevention of hospital-acquired infections are essential components of care. Limitations in resources mean that interventions for supportive care must be pragmatic. A report of neonatal care in training centres across Kenya found that all hospitals had oxygen, and 19/22 had resuscitation and phototherapy equipment [50] . Pragmatic interventions to improve respiratory support, beyond the provision of oxygen, have been recently described, using bubble CPAP in Uganda and Malawi, with promising findings [69, 70] . Similar progress needs to be made in terms of controlled fluid delivery to neonates; there were only 12/22 training centres across Kenya with paediatric burettes [50] . Uncontrolled or inadequate provision of intravenous fluids likely results in many undetected cases of electrolyte imbalance and consequent morbidity and mortality. Simple bedside tests are available for testing glucose levels, and temperature regulation can be improved by Kangaroo Mother Care, but these interventions need adequate staffing and health system support for implementation.
IMPROVING THE EVIDENCE
In contrast to the networks being set up in developed countries to report and monitor neonatal infections [37] , there are few health facilities in developing countries undertaking systematic clinical surveillance. Embedding clinical surveillance and using admission pro-forma facilitates clinical audit and monitoring and improves care. It will be increasingly possible to add microbiological diagnostic techniques to clinical surveillance platforms to improve understanding of the cause of disease and inform treatment guidelines. Reduced antibiotic susceptibility in both hospital and community-acquired infections represents an increasing threat to empiric treatment strategies, and more data are urgently needed [36, 71] . Methods such as whole genome sequencing will be able to shed new light on the epidemiology of infectious diseases worldwide, including transmission [72] , and antibiotic susceptibility [73] . Understanding these mechanisms in developing countries and identifying drivers of reduced antibiotic susceptibility are essential to inform prevention and control.
CONCLUSION
Effective management of neonatal sepsis in developing countries is essential to achieve further reductions in child mortality. Simplified antibiotic regimens are currently being examined in clinical trials, but reduced antimicrobial susceptibility threatens current empiric treatment strategies. Improved clinical and microbiological surveillance is essential, to inform current practice, treatment guidelines and monitor implementation of policy changes.
